Cara Therapeutics to Host KOL Meeting on Chronic Kidney Disease-Associated Pruritus on May 16, 2017
May 12 2017 - 4:01PM
Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company
focused on developing and commercializing new chemical entities
designed to alleviate pain and pruritus by selectively targeting
peripheral kappa opioid receptors, today announced that the Company
will host a key opinion leader (KOL) breakfast meeting focused on
CR845’s potential to treat patients with chronic kidney disease
(CKD)-associated pruritus on Tuesday, May 16, 2017 from 8:30 to
10:30 a.m. ET in New York.
The meeting will feature keynote presentations
from Steven Zeig, M.D., Nephrologist and Principal Investigator,
Pines Clinical Research Inc., and Shayan Shirazian, M.D.,
Nephrologist and Clinical Researcher, Winthrop-University Hospital
and Stony Brook University School of Medicine. Additionally,
executives from Cara will review the data from Part A of the Phase
2/3 trial in patients with CKD-associated pruritus and provide an
overview of the CR845 program.
A live audio webcast of the event and
accompanying slides can be accessed under “Events and
Presentations” in the News & Investors section of the Company’s
website at www.CaraTherapeutics.com.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage biotechnology company
focused on developing and commercializing new chemical entities
designed to alleviate pain and pruritus by selectively targeting
peripheral kappa opioid receptors. Cara Therapeutics is developing
a novel and proprietary class of product candidates that target the
body's peripheral nervous system and have demonstrated initial
efficacy in patients with moderate-to-severe pain and pruritus
without inducing many of the undesirable side effects typically
associated with currently available pain therapeutics.
INVESTOR CONTACT:
Michael Schaffzin
Stern Investor Relations
212-362-1200
michael@sternir.com
MEDIA CONTACT:
Annie Starr
6 Degrees
973-415-8838
astarr@6degreespr.com
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Apr 2024 to May 2024
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From May 2023 to May 2024